| Autor: |
Li-Hong Cui, Zhi Yang, Li Xu |
| Jazyk: |
angličtina |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
Guoji Yanke Zazhi, Vol 16, Iss 3, Pp 526-528 (2016) |
| Druh dokumentu: |
article |
| ISSN: |
1672-5123 |
| DOI: |
10.3980/j.issn.1672-5123.2016.3.34 |
| Popis: |
AIM:To observe the efficacy and safety of intravitreal Ranibizumab injection in patiens with choroidal neovascularization(CNV)secondary to pathologic myopia.METHODS:In this retrospective and comparative study,24 patients(25 eyes)with CNV secondary to pathologic myopia were enrolled. All patients were assessed by examinations of ETDRS visual acuity chart, preplaced-mirror ophthalmoscopy, fundus fluorescein angiography(FFA), indocyanine green angiography(ICGA)and optical coherence tomography(OCT). Patiens received intravitreally injected ranibizumab 0.5mg(0.05mL). Treatments were repeated if the follow-up indicated that it was necessary. The follow-up periods were 4～10mo. Best corrected visual acuity(BCVA), central macular thickness(CMT)and leakage of CNV before and after the treatment were compared. RESULTS:No local or systemic complications occurred in any patients during the treatment or follow-up. The average time of injection was 1.52. The mean BCVA was 23.93±12.46 letters before the therapy. In the last follow-up, the mean BCVA was 40.63±7.25 letters, improved by 14.27±9.36 letters and the difference was statically significant(t=5.74, Pt=3.96, PCONCLUSION:Intravitreal ranibizumab injection for CNV secondary to pathologic myopia is safe and effective, and this treatment can improve visual acuity, reduce retina edema and leakage of CNV. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
